Guidance
← 실적 발표
01
02
03
04 05 06
톤
A1 A2 A3 A4
INCY
FY2025 Q4
개선
Incyte Corporation 실적 발표
Buzzberg 분석
Core business ex-Jakafi expected to grow over 30% in 2026
Incyte reported strong Q4 and FY2025 results, beating guidance with 20% product revenue growth. Management guided 2026 to revenue of $4.77-4.94B, up 10-13%, and projected core (ex-Jakafi) growth of ~30%, driven by a maturing pipeline and multiple upcoming launches. The call focused on execution across oncology, hematology, and immunology, notably highlighting the pivotal data for Monjuvi in DLBCL and the potential for Povacitinib in HS, while managing expectations for Jakafi XR conversion. FY2025 total revenues grew 21% to $5.14B, with product sales up 20% to $4.35B, exceeding guidance.
Buzzberg 분석 Core business ex-Jakafi expected to grow over 30% in 2026 Incyte reported strong Q4 and FY2025 results, beating guidance with 20% product revenue growth. Management guided 2026 to revenue of $4.77-4.94B, up 10-13%, and projected core (ex-Jakafi) growth of ~30%, driven by a maturing pipeline and multiple upcoming launches. The call focused on execution across oncology, hematology, and immunology, notably highlighting the pivotal data for Monjuvi in DLBCL and the potential for Povacitinib in HS, while managing expectations for Jakafi XR conversion. FY2025 total revenues grew 21% to $5.14B, with product sales up 20% to $4.35B, exceeding guidance. 전체 분석 보기분석 접기
Incyte reported strong Q4 and FY2025 results, beating guidance with 20% product revenue growth. Management guided 2026 to revenue of $4.77-4.94B, up 10-13%, and projected core (ex-Jakafi) growth of ~30%, driven by a maturing pipeline and multiple upcoming launches. The call focused on execution across oncology, hematology, and immunology, notably highlighting the pivotal data for Monjuvi in DLBCL and the potential for Povacitinib in HS, while managing expectations for Jakafi XR conversion. FY2025 total revenues grew 21% to $5.14B, with product sales up 20% to $4.35B, exceeding guidance.
- Core business (ex-Jakafi) is guided to grow ~30% in 2026, driven by strong uptake of Monjuvi, Nictimbo, and Opsalura.
- Four key product launches are anticipated in late 2026/early 2027: Jakafi XR, Monjuvi in frontline DLBCL, Povacitinib for HS, and Opsalura for HS.
- Povacitinib NDA accepted, targeting large pre-biologic HS population as first oral treatment.
HEM_ONC 매출$0.583B보고값
JAKAFI 매출$3.093B보고값
OPSALURA 매출$0.678B보고값
PRODUCT_SALES 매출$4.35B보고값
근거 있는 핵심 내용 6개
지금 중요한 점
이번 발표에서 가장 의미 있는 변화를 정리했습니다.
Pipeline
Jakafi XR approval and launch expected mid-2026
Regulatory
Povacitinib NDA submitted for HS, filing acceptance this quarter
핵심 내용 3개 더 보기
Clinical Data
FrontMIND trial met primary endpoint PFS in first-line DLBCL
Pipeline
Opluura PN development paused after FDA feedback
Guidance
Management expects four product approvals in late 2026 and early 2027
보고 기간
보고 실적
| 지표 | 보고값 | 변화 |
|---|---|---|
| HEM_ONC 매출 | $0.583B | 보고값 |
| JAKAFI 매출 | $3.093B | 보고값 |
| OPSALURA 매출 | $0.678B | 보고값 |
| PRODUCT_SALES 매출 | $4.35B | 보고값 |
| 매출 | $1.5068B | 보고값 |
| 주당순이익(EPS) | $1.80 | 보고값 |
향후 전망
향후 가이던스
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| 영업이익률RD_SGA | FY2026 | $3.495B–$3.675B | $3.585B | 유지 |
| 매출 | FY2026 | $4.77B–$4.94B | $4.855B | 유지 |
| 매출JAKAFI | FY2026 | $3.22B–$3.27B | $3.245B | 유지 |
| 매출OPSALURA | FY2026 | $0.75B–$0.79B | $0.77B | 유지 |
| 매출HEM_ONC | FY2026 | $0.8B–$0.88B | $0.84B | 유지 |
| 매출CORE_EX_JACKIFY | FY2026 | $1.57B–$1.69B | $1.63B | 유지 |
AI, 자본지출 및 수요 분석
경영진 분석
Confident
Management expressed strong confidence in the pipeline and growth trajectory, emphasizing multiple catalysts and a clear path to replace Jakafi.
외부 신호
공급망 알파 · 4발표 이후 수익률
Incyte is executing a deliberate transition: expecting 4 product launches in late 2026/early 2027 (Jakafi XR, Monjuvi frontline DLBCL, Povacitinib HS, Opsalura), with the core business (ex-Jakafi) guided to ~30% growth in 2026.
근거
“Sales for our core business, X-Jackify, will range between $1.57 and $1.69 billion, representing roughly a 30% growth rate at the midpoint in 2026.”
Formulary negotiations for future Jakafi XR are in progress, with management expecting enough coverage to enable a 10-30% conversion rate from the IR version, contributing minimal revenue in 2026 but significant potential by 2029.
근거
“With an extended release formulation like Jackify, you're probably not going to reach into that top tier of formulary coverage. But we should get enough formulary coverage to enable a conversion rate of 10% to 30%.”
Incyte’s KRAS G12D (734) and TGF-betaR2xPD-1 (A9O) programs target 'wide open white spaces' in pancreatic and MSS colorectal cancer, aiming to be first or early to market with potential for significant market share.
근거
“These are, these are the largest wide open white spaces in cancer. We could be first or early in pancreatic and we could be first and only in colorectal.”
Povacitinib’s opportunity is to capture the 75% of HS patients not on advanced systemics, focusing on the pre-biologic population currently cycling through antibiotics/steroids.
근거
“There's 150,000 people using products that are not approved for HS, antibiotics, and steroids. Our ability to drive sales of povocitinib is to get to that group...”
방법론 및 범위
경영진 발언만 분석합니다. 검증된 기업 언급 0개를 모두 표시하며, 보고 실적과 향후 가이던스를 분리합니다. 공개 근거는 화자가 표시된 짧은 인용문 8개로 제한됩니다. AI 분석은 불완전하거나 틀릴 수 있으므로 중요한 주장은 원문에서 확인하세요.